Obesity-associated Mitophagy Resistance
Obesity-associated Mitophagy Resistance
批准号:
9750720
负责人:
Michael J. Jurczak
金额:
$35.21万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-25 至 2023-05-31
关键词:
AcetylationAffectBiochemicalBiologyCell RespirationCellsCitric Acid CycleConfocal MicroscopyDataDevelopmentDietDisciplineDiseaseEventExcisionFatty LiverFree RadicalsGenerationsGeneticHealthHepaticHomeostasisImpairmentIn VitroInsulin ResistanceKnowledgeLipidsLiverLiver MitochondriaLysineMass Spectrum AnalysisMediatingMetabolicMetabolic DiseasesMetabolic stressMitochondriaMitochondrial ProteinsModelingMolecularMusMutagenesisNon-Insulin-Dependent Diabetes MellitusNutritionalObese MiceObesityObesity associated liver diseaseOuter Mitochondrial MembraneOxidantsOxidative PhosphorylationPINK1 genePathogenesisPathologyPathway interactionsPhosphorylationPolyubiquitinPost-Translational Protein ProcessingPredispositionProductionProtein AcetylationProtein-Serine-Threonine KinasesProteinsProteomicsQuality ControlReactive Oxygen SpeciesReportingResearch DesignResistanceSignal PathwaySignal TransductionStressTestingTherapeuticThinnessUbiquitinUbiquitinationbasedesignimprovedin vivoinsightinsulin sensitivityinsulin signalinglifestyle interventionmitochondrial dysfunctionnovelobesity developmentrecruitstable cell linetargeted treatmentubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary/Abstract
Abnormal mitochondrial function is proposed to contribute to the hepatic insulin resistance and steatosis
associated with obesity and type 2 diabetes. Recently, diet-induced obesity in mice was found to be associated
with reduced rates of hepatic mitophagy, a mitochondrial quality control pathway that regulates selective
removal of damaged mitochondria from the cell. Mitophagy signaling and targeting of damaged mitochondria
relies on generation of a phosphorylated ubiquitin signaling motif on the outer mitochondrial membrane that is
produced through the coordinated activation of the ubiquitin E3 ligase PARKIN and the serine/threonine kinase
PINK1. This proposal will test the hypothesis that obesity-associated liver metabolic disease arises in part due
to a loss of mitochondrial homeostasis resulting from impaired PINK1-PARKIN-mediated signaling and
subsequently reduced mitophagy. The approach to test this hypothesis consists of characterizing a novel
mouse line with liver-specific deletion of PARKIN at baseline and during diet-induced obesity, and will include a
breadth of in vivo and ex vivo approaches designed to evaluate hepatic mitochondrial oxidative metabolism,
reactive oxygen species production, hepatic insulin sensitivity, rates of mitophagic flux, and changes in hepatic
insulin signaling and stress signaling pathways. These studies will define how genetic inhibition of PARKIN-
mediated mitophagy in liver impacts mitochondrial biology and the pathogenesis of obesity-associated liver
metabolic disease. Additionally, key aspects of PINK1-PARKIN-mediated mitophagy signaling will be evaluated
in lean and obese mice using a combination of approaches that includes quantitative mass spectrometry-
based proteomics, confocal microscopy and mutagenesis followed by in vivo and in vitro functional
characterization using primary and stable cell lines and cell free models. These studies will define how
nutritional stress in the obese liver contributes to post-translational modifications of mitochondrial proteins that
then interfere with recently defined phosphorylation and ubiquitination signaling events that activate the
mitophagy pathway. They will provide further insight into how PINK1 and PARKIN dynamics are affected in the
obese liver and may account for the reduced mitophagy observed in liver from diet-induced obese mice.
Overall, these studies will explore a novel pathway by which nutritional stress in liver may contribute to the
pathogenesis of hepatic steatosis, insulin resistance and mitochondrial dysfunction. This new knowledge will
ultimately improve our understanding of the biochemical and molecular events that contribute to these
diseases, which may lend themselves to the development of effective life style interventions or targeted
therapeutics to treat obesity-associated liver disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD
-
批准号:10533324
-
项目类别:
-
资助金额:$40.86万
-
财政年份:2019
-
负责人:Michael J. Jurczak
-
依托单位:
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD
-
批准号:10321596
-
项目类别:
-
资助金额:$40.86万
-
财政年份:2019
-
负责人:Michael J. Jurczak
-
依托单位:
Obesity-associated Mitophagy Resistance
-
批准号:10402821
-
项目类别:
-
资助金额:$35.21万
-
财政年份:2018
-
负责人:Michael J. Jurczak
-
依托单位:
Obesity-associated Mitophagy Resistance
-
批准号:10165704
-
项目类别:
-
资助金额:$35.21万
-
财政年份:2018
-
负责人:Michael J. Jurczak
-
依托单位:
Park2,impaired lipid absorption and protection from diet-induced obesity
-
批准号:9229747
-
项目类别:
-
资助金额:$7.74万
-
财政年份:2017
-
负责人:Michael J. Jurczak
-
依托单位:
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance
-
批准号:9117027
-
项目类别:
-
资助金额:$11.79万
-
财政年份:2013
-
负责人:Michael J. Jurczak
-
依托单位:
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance
-
批准号:8566479
-
项目类别:
-
资助金额:$14.71万
-
财政年份:2013
-
负责人:Michael J. Jurczak
-
依托单位:
海外基金